A multimodal MRI radiomics and deep learning model outperformed traditional models in predicting 5- and 7-year survival for breast cancer patients receiving neoadjuvant chemotherapy.
Key Details
- 1Study involved 216 women with breast cancer post-neoadjuvant chemotherapy.
- 2Model integrated MRI radiomics, pathology, and clinical data using deep learning.
- 3The deep feature-based patho-radiomic model achieved AUCs of 0.89 (training) and 0.82 (test) for 5-year survival, and 0.91 (training) and 0.87 (test) for 7-year survival.
- 4Clinical-only models showed lower AUCs (0.4–0.53 for 5-years; 0.45–0.53 for 7-years).
- 5Traditional clinical and molecular markers (ER, HER2, TNBC) did not significantly predict survival in this cohort.
- 6Authors advocate for prospective studies to guide clinical decisions using the model.
Why It Matters
This research demonstrates the power of combining imaging, pathology, and clinical data through AI to provide more accurate long-term prognostic tools in oncology, surpassing traditional clinical or single-modality models. Improved risk stratification could optimize therapeutic decision-making and patient counseling in breast cancer care.
Source
AuntMinnie
Related News
•Radiology Business
New AI Flags Uncertainty in Breast Cancer Imaging Predictions
University of Pittsburgh researchers developed an AI model that quantifies uncertainty in breast cancer diagnostic predictions to enhance trustworthiness.
•Radiology Business
FDA Approves SimBioSys AI Tool for Breast Cancer Risk via MRI
SimBioSys received FDA clearance for TumorSight Risk, an AI tool assessing breast cancer recurrence risk using MRI.
•AuntMinnie
LLMs Rarely Recommend Unnecessary Imaging, Except for Thyroid Ultrasound
Large language models seldom over-recommend imaging, but thyroid ultrasound guidance shows substantial discrepancies.